吴瑞瑞

A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance.

Sun L, Wan AH, Yan S, Liu R, Li J, Zhou Z, Wu R, Chen D, Bu X, Ou J, Li K, Lu X, Wan G*, Ke Z*.

Acta Pharm Sin B. 2024 Jan;14(1):223-240.·2024·DOI